Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapsepreventive immunotherapy in acute myeloid leukaemia Relapse after the completion of induction and consolidation chemotherapy remains a significant cause of mortality in the post-chemotherapy phase of acute myeloid leukaemia (AML). Several studies have questioned whether AML patients who require two or more courses of induction chemotherapy to attain complete remission (CR) are at increased risk of relapse or death. While studies performed in the 1980's and 1990's yielded inconclusive results (Rowe et al., 2010) , contemporary studies have identified that needing more than one cycle of induction chemotherapy to achieve CR is a risk factor for relapse and death in younger adult patients (Othus et al., 2019) .
Aspects of immunity are relevant to the relapse risk in AML and several immunotherapies aimed at preventing relapse have been developed (Martner et al., 2013; Weinstock et al., 2017; Beyar-Katz & Gill, 2018; Liu et al., 2019) .
Immunotherapy with histamine dihydrochloride in conjunction with low-dose interleukin-2 (HDC/IL-2) is approved for relapse prevention in AML patients within the European Union (EU). For this study, we analysed the potential impact of previous induction chemotherapy on the clinical efficacy of HDC/IL-2.
Three hundred and twenty patients with AML (18-84 years, median 55), who were not eligible for allogeneic stem cell transplantation, were randomly assigned to receive relapse-preventive immunotherapy with HDC/IL-2 or no treatment (control group) in a phase III trial. HDC/IL-2 was initiated in CR after consolidation chemotherapy (Brune et al., 2006) . Patients in the treatment arm were scheduled to receive 10 consecutive three-week cycles of HDC/IL2 with three-(cycles 1-3) or six-week (cycles 4-10) rest periods. In each cycle, these patients received HDC (Noventia Pharma, This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. 
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Milan, Italy) at 0Á5 mg and human recombinant low-dose IL-2 (aldesleukin; 16 400 IU/kg; Chiron Corporation, Emeryville, CA) subcutaneously twice a day. After 18 months of treatment, patients were monitored for at least 18 additional months. The median follow-up time was 48 months.
In the CR1 population (n = 261), the number of induction cycles was known in 260 patients, and 203 (78%) of these attained CR after one induction cycle. Among the 57 remaining patients, 47 attained CR after two cycles, while three (n = 7) or four (n = 3) cycles were required to induce CR in 10 patients. Among control patients, there was a nonsignificant trend towards inferior clinical outcome in terms of leukemia-free survival (LFS, defined as the time from inclusion to relapse or death) in those who required more than one induction to attain CR, with a similar trend in younger patients (<60 years old; Figure S1A -B). In the HDC/ IL-2 arm, outcome was significantly superior in patients who attained CR1 after one induction for all patients as well as for younger patients (Figure S1C-D). In multivariable analyses, it was found that the number of induction cycles required to attain CR independently predicted outcome for patients in the treatment arm (Table S1) .
We compared clinical outcomes for HDC/IL-2-treated and control patients who achieved CR after one cycle of induction. In this group, the HDC/IL-2 arm was significantly superior to the control arm for LFS, with a similar trend for overall survival (OS; Figure 1A -B). In patients less than 60 years old, treatment with HDC/IL-2 entailed significantly improved LFS and OS ( Figure 1C -D). The survival advantage for patients in the treatment arm over the control arm remained significant in multivariable analyses (Table I) , correcting for predefined potential confounders (Brune et al., 2006) . Treatment with HDC/IL-2 did not affect LFS or OS in patients who required more than one cycle of induction to attain CR1 ( Figure 1E -F) and was not significantly beneficial in older patients (>60 years old; data not shown). A test of interaction on the effect of HDC/IL-2 versus controls for LFS supported the finding that it was more pronounced in younger patients who attained CR after one (HR = 0Á48) versus more than one (HR = 1Á33) cycle of induction (P = 0Á04).
The HDC component of the HDC/IL-2 regimen aims at countering immunosuppression triggered by reactive oxygen species, formed by the NOX2 enzyme expressed by normal and malignant myeloid cells (Martner et al., 2013; Martner et al., 2019) . In AML, functional NOX2 is co-expressed with histamine H 2 receptors (H 2 R) by leukaemic cells of the M4 and M5 FAB classes (Aurelius et al., 2012a; Aurelius et al., 2012b) . We analysed the impact of induction chemotherapy on treatment efficacy in younger patients with FAB M4/M5 AML and observed pronounced efficacy of HDC/IL-2 versus controls in terms of LFS and OS in patients who attained CR1 after one induction in univariable and multivariable analysis ( Figure S2 , Table I ).
We conclude that the clinical efficacy of relapse-preventive immunotherapy with HDC/IL-2 hinges on the effectiveness of induction chemotherapy. In this regard, our results confirm and extend previous findings in a single-arm phase IV trial in which 84 AML patients in CR1 received HDC/IL-2 (Aurelius et al., 2019) . In addition, similar results of favourable outcome in patients achieving CR after one versus several cycles of induction were obtained in AML patients undergoing allogeneic transplantation (Walter et al., 2013) . Collectively, these results suggest that efficient elimination of leukemic cells during induction treatment favours immunemediated clearance of residual leukaemia, thus preventing relapse and death in the post-chemotherapy phase.
Within the group of patients attaining CR after one induction cycle, our data also point to subgroups of patients, including FAB-M4/M5 AML, in whom the clinical efficacy of HDC/IL-2 for relapse prevention is pronounced. These results thus provide means to identify patients who are likely to benefit from immunotherapy and, conversely, patients in Table I . Cox regression analysis of effects of HDC/IL-2 treatment versus control on LFS or OS in patients in CR1 who attained CR after one induction cycle. Covariates that tended to affect LFS or OS in univariable analyses (P-values below 0Á1) were included in multivariable analyses.
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Univariable analysis Multivariable analysis † e51 whom the therapy is inefficacious. The exploratory nature of these results should be emphasised. In summary, our results imply that the efficiency of induction chemotherapy independently determines the clinical benefit of relapse-preventive immunotherapy with HDC/ IL-2 in adult AML patients who are not candidates for allogeneic transplantation. This finding, along with similar results achieved in patients receiving allo-SCT, suggests that future immunotherapy trials should take the efficiency of induction therapy into account. Table S1 . Cox regression analysis of the effect of 1 versus >1 induction cycle of chemotherapy on LFS or OS in patients in CR1. Covariates with P-values below 0.1 in univariable analyses were included in multivariable analyses. Figure S1 . Kaplan-Meier plots of LFS in all control arm patients in CR1 (A) and in younger control patients (<60 years old, B) who attained CR after 1 versus >1 course of induction chemotherapy. Panels C and D show corresponding results in the HDC/IL-2 arm. Statistics by the logrank test. Figure S2 . Kaplan-Meier plots of LFS (A) and OS (B) in younger patients (<60 years old) with AML of FAB M4/M5 classes receiving HDC/IL-2 or control who attained CR1 after the first course of induction chemotherapy. Statistics by the logrank test. In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation Mutations in SAMD9 or SAMD9L are found in patients with familial predisposition to myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) associated with both MIRAGE syndrome (Myelodysplasia, Infection, Restriction of growth, Adrenal hypoplasia, Genital phenotypes, and Enteropathy) and ATXPC (ataxia-pancytopenia syndrome) (Li et al., 1981; Narumi et al., 2016; Chen et al., 2016) , respectively. The wild-type (WT) function of SAMD9 and SAMD9L in haematopoietic cell lines is antiproliferative. Germline mutations are thought to be gain-of-function (GOF) mutations, exacerbating the antiproliferative effects of the WT gene (Tesi et al., 2017; Buonocore et al., 2017; Davidsson et al., 2018) . Functional somatic reversion through either loss of heterozygosity (À7 or 7q-) or uniparental disomy (UPD), or through acquisition of loss of function (LOF) mutations, has been described in affected individuals. Thus far, LOF mutations have been described in cis for SAMD9, but rarely in trans for SAMD9L (Nagata et al., 2018; Wong et al., 2018) . Here we present a four-generation pedigree affected by AML and MDS, with novel disease features and a reversion mutation in trans, consistent with germline mosaicism. The proband (III-1) presented in 1986 aged 10 with a history of excessive bruising. She was one of four siblings, two of which were stillborn. She was also noted to have an extensive family history of MDS and AML; specifically, her mother (II-1) had MDS, an aunt (II-4) died of AML aged 11 following MDS, a cousin (III-5) died of AML aged eight and her mother's cousin (II-8) died of leukaemia ( Fig 1A) . Her haematological parameters at presentation were normal, except for abnormal platelet function tests. In 1998 (aged 22) she developed tri-lineage cytopenias. Bone marrow aspirate (BMA) at this time showed MDS with 7q-in 5/30 metaphases (46,XX,del (7) Her daughter, IV-1, was born in 1996 at 28 weeks due to severe IUGR. Blood count at birth showed thrombocytopenia (90x10 9 /l), presumed to be due to prematurity. However, aged two, she was noted to have anaemia (Hb 9.1g/dl) as well as thrombocytopenia (65x10 9 /l). A BMA showed MDS with NK. She underwent an unrelated donor transplant at the age of four. Pre-transplant assessment noted that she had global developmental delay. She died two months post-transplant due to Epstein-Barr virusrelated disease.
The proband had five additional pregnancies. IV-3 was complicated by severe polyhydramnios and the pregnancy was terminated because of concerns regarding congenital anomalies. IV-5 is alive and well, aged 10.
Informed consent was obtained from the UCL/UCLH Biobank for Studying Health and Disease. Whole exome sequencing was undertaken on stored bone marrow DNA of the proband from 2015, which identified two non-synonymous base changes in SAMD9 c.2958C> Gresulting in S986Cand c.1447C> Gresulting in p.L483V ( Fig 1B) . In silico analyses of these variants suggested both mutations were likely to be pathogenic ( Fig 1C) .
To determine if the mutations found in the proband were present in other family members, we undertook targeted deep sequencing of the regions surrounding the SAMD9 variants in IV-1 and the proband's mother (II-1) along with additional available samples from IV-5 and III-1 ( Fig 1D) . III-1, IV-1 and II-1 carried L483V at allele frequencies consistent with germline origin. The S986C variant was present only in samples from III-1. Here it was present at an allele frequency of 21% in the peripheral blood (2001) and 30Á4% in the BMA from 2015. Matched buccal swab (2015) also showed this variant but at a lower allele frequency (17%). To determine whether this was due to blood contamination, we obtained nail clippings from III-1. This revealed the presence of the S986C mutation at a low frequency of 3Á6%. This suggests that the proband
